Is Glenmark Pharma overvalued or undervalued?

Nov 16 2025 08:10 AM IST
share
Share Via
As of November 14, 2025, Glenmark Pharma is considered overvalued with a PE ratio of 47.78, significantly higher than its peers, despite a strong past year performance of 22.94%, indicating that its current valuation metrics are not justified.
As of 14 November 2025, Glenmark Pharma's valuation grade has moved from fair to expensive, indicating a shift in its market perception. The company is currently overvalued, with a PE ratio of 47.78, a Price to Book Value of 6.03, and an EV to EBITDA ratio of 23.11. These figures suggest that the stock is trading at a premium compared to its earnings and book value.

In comparison to its peers, Glenmark Pharma's PE ratio significantly exceeds that of Sun Pharma, which stands at 36.49, and is much higher than the more attractively valued Cipla, with a PE ratio of 22.72. Notably, while Glenmark has a PEG ratio of 0.19, indicating potential growth, its overall valuation metrics suggest it is not justified at current price levels. Additionally, Glenmark has outperformed the Sensex over the past year, returning 22.94% compared to the Sensex's 9.00%, but this performance does not mitigate the concerns regarding its current overvaluation.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News